Diffuse large B-cell lymphoma (DLBCL) is diagnosed through a combination of tissue biopsy, laboratory staining, genetic testing, and imaging scans. It is the most common type of non-Hodgkin lymphoma, making up 25% to 30% of all cases. Because DLBCL is aggressive and often grows quickly, the diagnostic process moves fast and involves several steps to confirm the type, subtype, and stage of the disease.
How DLBCL Typically Presents
DLBCL usually shows up as a rapidly growing lump or swollen lymph nodes, either in the lymph system itself or in organs outside it. Many people also experience what doctors call B symptoms: unexplained fevers, drenching night sweats, and losing more than 10% of body weight over six months. Around 30% to 35% of patients have B symptoms at the time of diagnosis, though the rate depends heavily on how advanced the disease is. Only about 16% of people diagnosed at the earliest stage have B symptoms, while that number rises to roughly 41% in stage IV disease.
Because DLBCL spreads through the bloodstream, most people already have advanced disease (stage III or IV) by the time they’re diagnosed. That can sound alarming, but it’s worth knowing that up to 50% of patients who achieve complete remission with first-line treatment are cured.
Biopsy: The Essential First Step
A biopsy is the only way to confirm DLBCL. The gold standard is an excisional biopsy, where a surgeon removes an entire lymph node or a large piece of tissue. This gives pathologists enough material to examine the tissue’s structure under a microscope, run specialized staining tests, and extract DNA and RNA for genetic analysis. All of that information matters for pinning down the exact diagnosis.
The downside of excisional biopsy is that it typically requires general anesthesia and can involve delays while arranging surgery. When that procedure is too risky for a patient, a core needle biopsy is the alternative. Multiple long cores (10 to 15 mm each) can sometimes provide enough tissue. However, single thin cores of 5 mm or less severely limit the quality of every test that follows. If a needle biopsy doesn’t yield a clear diagnosis, guidelines recommend proceeding to an excisional biopsy rather than repeating the needle approach.
What Pathologists Look for Under the Microscope
Once the tissue is in the lab, pathologists use a technique called immunohistochemistry, which applies special stains to identify proteins on the surface of the cancer cells. DLBCL cells are positive for a protein called CD20, a marker found on B cells. This is a key identifier and also the target of a widely used treatment antibody.
Beyond confirming the diagnosis, pathologists need to determine the subtype. DLBCL falls into two major molecular categories: germinal center B-cell (GCB) and activated B-cell (ABC, also called non-GCB). These subtypes behave differently and can respond differently to treatment. The most common method for sorting them is the Hans algorithm, which checks for three protein markers using a 30% positivity cutoff. If a marker called CD10 is positive, the case is classified as GCB. If CD10 is negative but BCL6 is positive and MUM1 is negative, it’s still GCB. All other combinations fall into the non-GCB category. While gene expression profiling is more precise, the Hans algorithm is practical and widely available.
Genetic Testing for High-Risk Disease
After confirming the diagnosis and subtype, labs test for specific genetic rearrangements that signal a more aggressive form of the disease. The most important of these involve a gene called MYC. When MYC is rearranged alongside another gene called BCL2, the lymphoma is classified as “double-hit.” When MYC is rearranged with both BCL2 and BCL6, it’s called “triple-hit.” These designations matter because double-hit and triple-hit lymphomas tend to be harder to treat and often require more intensive therapy.
The latest World Health Organization classification (5th edition) reflects how central these genetic findings have become. Cases with both MYC and BCL2 rearrangements are now grouped under the name “diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements,” regardless of how the cells look under the microscope. Cases with MYC and BCL6 rearrangements (but not BCL2) are classified separately and treated as a distinct genetic subtype. This testing is done using a technique called FISH (fluorescence in situ hybridization), which detects specific breaks in chromosomes.
Imaging and Staging
Once the biopsy confirms DLBCL, a PET-CT scan is the primary tool for determining how far the disease has spread. PET-CT combines a metabolic scan that highlights areas of high cell activity with a detailed structural image of the body. It plays a central role in initial staging, detecting disease outside the lymph nodes, and later in assessing treatment response.
Staging follows the Lugano classification, a modified version of the older Ann Arbor system:
- Stage I: Cancer in one lymph node group or one organ site outside the lymph system
- Stage II: Two or more lymph node groups on the same side of the diaphragm (the muscle dividing your chest from your abdomen)
- Stage III: Lymph node groups on both sides of the diaphragm, or nodes above the diaphragm plus involvement of the spleen
- Stage IV: Disease that has spread beyond the lymph system into organs like the liver, lungs, or bone marrow
Bone marrow involvement is particularly important for staging. PET-CT has improved detection significantly, since the traditional bone marrow biopsy (a needle sample from the hip bone) catches only about 27% of patients with confirmed bone marrow disease. PET-CT picks up many cases that biopsy misses. That said, whether PET-CT can fully replace bone marrow biopsy remains an ongoing debate, and many centers still perform both.
The Prognostic Score at Diagnosis
At the time of diagnosis, your medical team will calculate something called the International Prognostic Index (IPI), a score that helps predict how the disease is likely to respond to treatment. It’s based on five yes-or-no factors:
- Age: Over 60 years old
- Stage: Stage III or IV disease
- LDH level: An elevated blood enzyme that signals faster cell turnover
- Performance status: How well you’re able to carry out daily activities
- Extranodal sites: Disease in more than one location outside the lymph nodes
Each factor adds one point. A higher score indicates a greater risk, which helps guide treatment intensity. The IPI doesn’t predict what will happen to any individual person, but it gives doctors a framework for tailoring the approach. Someone with a low IPI score and GCB subtype, for example, generally has a more favorable outlook than someone with a high score and double-hit genetics.
Newer Subcategories in the Latest Classification
The 2022 WHO classification introduced several refined categories that pathologists now look for during diagnosis. EBV-positive DLBCL is a subtype in which the cancer cells carry the Epstein-Barr virus. Lymphomas arising in “immune-privileged sites,” meaning areas the immune system doesn’t patrol as aggressively (the brain, the eye, and the testes), are now grouped together as their own entity. A rare, slow-growing form called fibrin-associated large B-cell lymphoma has also been upgraded to a distinct diagnosis rather than a variant.
These distinctions aren’t just academic. Each subtype can behave differently, respond to different treatments, and carry a different prognosis. The growing precision of DLBCL diagnosis reflects a broader shift: what was once treated as a single disease is now understood as a family of related but distinct cancers, each requiring its own diagnostic workup and treatment strategy.